Abstract:HCC stem cells were reported as posttreatment residual tumor cells that play a pivotal role in tumor relapse. Fusing dendritic cells (DCs) with tumor cells represents an ideal approach to effectively activate the antitumor immunity in vivo. DC/HCC stem cell vaccine provides a potential strategy to generate polyclonal immune response to multiple tumor stem cell antigens including those yet to be unidentified. To assess the potential capacity of DC/HCC stem cell vaccines against HCC, CD90+HepG2 cells were sorted from the HCC cell line HepG2. DC and CD90+HepG2 and DC and HepG2 fused cells were induced by polyethylene glycol (PEG). The influence of fusion cells on proliferation and immunological function transformation of lymphocytes was assessed by FCM and ELISA assay, respectively. The cytotoxicity assay of specific fusion cell-induced CTLs against HepG2 was conducted by CytoTox 96 Non-Radioactive Cytotoxicity Assay kit in vitro. At last, the prevention of HCC formation in vivo was described in a mouse model. The results of FCM analysis showed that the proportion of CD90+HepG2 cells in the spheral CD90+HepG2 enriched by suspension sphere culture was ranging from 98.7% to 99.5%, and 57.1% CD90+HepG2/DC fused cells were successfully constructed. The fusion cells expressed a higher level of costimulatory molecules CD80, CD83, CD86, and MHC-I and MHC-II molecules HLA-ABC and HLA-DR than did immature DCs (P < 0.05). And the functional analysis of fusion cell-induced CTLs also illustrated that CD90+HepG2/DC fusion cells showed a greater capacity to activate proliferation of lymphocytes in vitro (P < 0.05). The CD90+HepG2/DC-activated CTLs had a specific killing ability against CD90+HepG2 cells in vivo. These results suggested that CD90+HepG2/DC fusion cells could efficiently stimulate T lymphocytes to generate specific CTLs targeting CD90+HepG2 cells. It might be a promising strategy of immunotherapy for HCC.

[In Vitro Antitumor Immune Response Induced by Fusion of Dendritic Cells and Ewing's Sarcoma Cells].

Dendritic Cell-Ewing'S Sarcoma Cell Hybrids Enhance Antitumor Immunity

In Vitro Antitumor Immune Response Induced By Fusion Of Dendritic Cells And Colon Cancer Cells

Allogenic Γδ T Cell and Tumor Cell Fused Vaccine for Enhanced Immunotherapeutic Efficacy of Osteosarcoma

Activation of antitumor cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous osteosarcoma

Antitumor Effect of Immunizations with Fusions of Dendritic and Hepatocellular Carcinoma Cells in Mice

Therapeutic immune response induced by electrofusion of dendritic and tumor cells

Dendritic Cells Loaded with Ultrasound-Ablated Tumour Induce in Vivo Specific Antitumour Immune Responses

Immunotherapy of Intracranial G422 Glioblastoma with Dendritic Cells Pulsed with Tumor Extract or RNA

[Construction of Recombinant Adenoviral Vector Containing Gene of EWS-FLI1 and Antitumor Immunity of Its Modified Dentritic Cell in Vitro].

Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols

Immunological suppression of head and neck carcinoma by dendritic cell tumor fusion vaccine.

A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma

Specific Inhibition Of Tumor Growth By T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen Ny-Eso-1/Lage-1

A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dentritomas

Dendritic Cells Pulsed With Gst-Egfr Fusion Protein: Effect In Antitumor Immunity Against Head And Neck Squamous Cell Carcinoma

Ewing Sarcoma-Derived Extracellular Vesicles Impair Dendritic Cell Maturation and Function

Recombinant Human Programmed Cell Death 5 Combined with Doxorubicin Induced Apoptosis of Ewing Sarcoma in Vitro

In vitro study of anti-tumor immunity of the EWS-FLI1 gene and hGM-CSF gene modified-dendritic cells

Antitumor Effect of Immunization with Fusion of Dendritic Cells and Hepatocellular Carcinoma Cells in Mice.

Dendritic Cells Pulsed with Α‐fetoprotein and Mutant P53 Fused Gene Induce Bi‐targeted Cytotoxic T Lymphocyte Response Against Hepatic Carcinoma